BCBS Kansas City Medical Policy Updates – September 2018

Click here to view the Blue Cross Blue Shield Kansas City Medical Policy Updates »

September 2018 BCBS Kansas City Medical Policy Updates:

• ADHD Non-Stimulant Step Therapy Policy
• ADHD Stimulant ST Policy
• Alpha Blockers for BPH ST policy
• Alpha Reductase Inhibitors BPH Step Therapy Policy
• Alzheimer%27s Disease ST policy
• Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry
• Antidepressants – SNRI Step Therapy Policy
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer
• Automated Ambulatory Blood Pressure Monitoring
• Balloon Ostial Dilation for Treatment of Chronic Rhinosinusitis
• Beta-Blockers ST policy
• Bile Acid Sequestrants ST policy
• Bisphosphonates (oral) ST policy
• Bronchial Thermoplasty
• Cardiac Rehabilitation
• Chronic Intermittent Intravenous Insulin Therapy
• Cimzia (certolizumab)
• Cochlear Implants
• Combination Beta2-Agonist Corticosteroid Inhalers PA policy
• Confocal Laser Endomicroscopy
• Continuous or Intermittent Glucose Monitoring in Interstitial Fluid
• Cryosurgical Ablation of Miscellaneous Solid Tumors Other than Liver Prostate or Dermatologic Tumors
• Depakote-Depakene Step Therapy Program
• Diagnosis and Medical Management of Obstructive Sleep Apnea Syndrome
• Dopamine Transporter Imaging With Single Photo Emission CT
• Dry Needling of Myofascial Trigger Points
• Electromagnetic Navigation Bronchoscopy
• Eliquis (apixaban)
• Enbrel (etanercept)
• Endobronchial Brachytherapy
• Endovascular Stent Grafts for Disorders for the Thoracic Aorta
• External Portable Infusion Pumps
• Extracorporeal Photopheresis
• Extracorporeal Shock Wave Therapy for Plantar Fasciitis and Other Musculoskeletal Conditions
• Facet Arthroplasty
• Genetic Testing for FLT3 and NPM1 Variants in Cytogenetically Normal Acute Myeloid Leukemia
• Gout Medications ST policy
• Humira (adalimumab)
• Immune Globulin Therapy (Updated 8-18)
• Immune Prophylaxis for Respiratory Syncytial Virus (RSV) (rev 8-18)
• Implantable Sinus Stents for Postoperative Use Following Endoscopic Sinus Surgery
• Interspinous and Interlaminar Stabilization Distraction Devices
• Intraocular Radiation Therapy for Age Related Macular Degeneration
• Jynarque (tolvaptan)
• Laparoscopic and Percutaneous Techniques for the Myolysis of Uterine Fibroids
• Long-Acting Opioid Step Therapy Policy
• Manipulations and Chiropractic Care
• Measurement of Exhaled Nitric Oxide
• Molecular Markers in Fine Needle Aspirates of the Thyroid
• Multimarker Serum Testing Related to Ovarian Cancer
• Negative Pressure Wound Therapy in outpatient setting
• Neurofeedback
• Ophthalmic Prostaglandin Step Therapy
• Ophthalmologic Techniques that evaluate Posterior Segment for Glaucoma
• Opthalmic Dry Eye Disease – Restasis (cyclosporine ophthalmic emulsion)
• Orthopedic App of Stem Cell Therapy
• PDF: 09-18 10 Facility Routine Supplies and Services
• Percutaneous Balloon Kyphoplasty and Mechanical Vertebral Augmentation
• Peripheral Subcutaneous Field Stimulation
• Peroral Endoscopic Myotomy for Treatment of Esophageal Achalasia
• Pradaxa (dabigatran) PA policy
• Proteogenomic Testing for Patients With Cancer
• Radiofrequency Ablation of Peripheral Nerves to Treat Pain
• Radiofrequency Ablation of Primary or Metastatic Liver Tumors
• Sabril, Vigadrone (vigabatrin)
• Scintimammography and Gamma Imaging of Breast Axilla
• Selzentry (maraviroc) PA policy
• Sensory Integration Therapy and Auditory Integration Therapy
• Short-Acting Fentanyl
• Solaraze (diclofenac sodium 3 percent gel)
• Sovaldi (sofosbuvir)
• Spinal Ultrasound
• Surgery for Groin Pain in Athletes
• Surgical Ventricular Restoration
• Symlin (pramlintide)
• Synthetic Cartilage Implants for Joint Pain
• Testosterone Replacement Therapies
• Therapeutic Radiopharmaceuticals in Oncology
• Thiazolidinedione ST policy
• Tramadol Step Therapy Policy
• Transcutaneous Electrical Nerve Stimulation
• Treatment of Tinnitus
• Triptans Step Therapy Policy
• Triptans Step Therapy Policy (ACA)
• Tumor Treatment Fields Therapy
• Urinary Biomarkers for Cancer Screening Diagnosis Surveillance
• Viscocanalostomy and Canaloplasty
• Xarelto (rivaroxaban)

Click here to view the Blue Cross Blue Shield Kansas City Medical Policy Updates »

Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!

Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.